Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Гломерулярные болезни: фокально-сегментарный гломерулосклероз

Список литературы

  1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int, Suppl 2012;2:139-274. https://kdigo.org/wp-content/uploads/2017/02/KDIGO-2012-GN- Guideline-English.pdf
  2. Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997;30(5):621-31. doi: 10.1016/s0272-6386(97)90485-6
  3. Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996;27:647-51. doi: 10.1016/s0272- 6386(96)90098-0
  4. Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol 2017;12(3):502-517. doi: 10.2215/CJN.05960616
  5. Fogo AB. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat Rev Nephrol 2015;11(2):76-87. doi: 10.1038/nrneph.2014.216
  6. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010;5(11):2115-21. doi: 10.2215/CJN.03800609
  7. Candelier JJ, Lorenzo HK. Idiopathic nephrotic syndrome and serum permeability factors: a molecular jigsaw puzzle. Cell Tissue Res 2020;379(2):231-243. doi: 10.1007/s00441-019-03147-y
  8. Abdi R, Dong VM, Rubel JR et al. Correlation between glomerular size and long-term renal function in patients with substantial loss of renal mass. J Urol 2003;170(1):42-4. doi: 10.1097/01.ju.0000069821.97385.6b
  9. D'Agati VD, Chagnac A, de Vries APJ et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol 2016;12(8):453-71. doi: 10.1038/nrneph.2016.75
  10. Cunningham EE, Zielezny MA, Venuto RC. Heroin-associated nephropathy. A nationwide problem. JAMA 1983;250(21):2935-6
  11. Barri YM, Munshi NC, Sukumalchantra S et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004;65(2):634-41. doi: 10.1111/j.1523-1755.2004.00426.x
  12. Dressler D, Wright JR, Houghton JB, Kalra PA. Another case of focal segmental glomerulosclerosis in an acutely uraemic patient following interferon therapy. Nephrol Dial Transplant 1999;14(8):2049-50. doi: 10.1093/ndt/14.8.2049
  13. Herlitz LC, Markowitz GS, Farris AB et al. Development of focal segmental glomerulosclerosis after anabolic steroid abuse. J Am Soc Nephrol 2010;21(1):163-72. doi: 10.1681/ASN.2009040450
  14. Santella RN, Rimmer JM, MacPherson BR. Focal segmental glomerulosclerosis in patients receiving lithium carbonate. Am J Med 1988;84(5):951-4. doi: 10.1016/0002- 9343(88)90077-0
  15. Mohamed N, Goldstein J, Schiff J, John R. Collapsing glomerulopathy following anthracycline therapy. Am J Kidney Dis 2013;61(5):778-81. doi: 10.1053/j.ajkd.2012.08.048
  16. Meehan SM, Pascual M, Williams WW et al. De novo collapsing glomerulopathy in renal allografts. Transplantation 1998;65(9):1192-7. doi: 10.1097/00007890-199805150-00009
  17. Izzedine H, Brocheriou I, Frances C. Post-transplantation proteinuria and sirolimus. N Engl J Med 2005;353(19):2088-9. doi: 10.1056/NEJM200511103531922…..
  18. Malone AF, Phelan PJ, Hall G et al. Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. Kidney Int 2014;86(6):1253-9. doi: 10.1038/ki.2014.305
  19. Hinkes BG, Mucha B, Vlangos CN et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007;119(4):e907-19. doi: 10.1542/peds.2006-2164
  20. Boyer O, Benoit G, Gribouval O et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol 2011;22(2):239-45. doi: 10.1681/ASN.2010050518
  21. Rivera F, López-Gómez JM, Pérez-García R, Spanish Registry of Glomerulonephritis. Clinicopathologic correlations of renal pathology in Spain. Kidney Int 2004;66(3):898- 904. doi: 10.1111/j.1523-1755.2004.00833.x
  22. Hommos MS, De Vriese AS, Alexander MP et al. The incidence of primary vs secondary focal segmental glomerulosclerosis: a clinicopathologic study. Mayo Clin Proc 2017; 92(12):1772-1781. doi: 10.1016/j.mayocp.2017.09.011
  23. Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis 2004;44(5):815-25
  24. Yao T, Udwan K, John R et al. Integration of Genetic Testing and Pathology for the Diagnosis of Adults with FSGS. Clin J Am Soc Nephrol 2019;14(2):213-223. doi: 10.2215/CJN.08750718
  25. Хроническая болезнь почек (ХБП). Клинические рекомендации. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf
  26. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150(9):604-12. doi: 10.7326/0003-4819-150-9- 200905050-00006
  27. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010;55(4):622-7. doi: 10.1053/j.ajkd.2010.02.337
  28. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis 2004;43(2):368-82. doi: 10.1053/j.ajkd.2003.10.024
  29. De Vriese AS, Sethi S, Nath KA et al. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol 2018; 29(3):759-774. doi: 10.1681/ASN.2017090958
  30. Rao TKS. Renal complications in HIV disease. Med Clin North Am 1996;80(6):1437-51
  31. Winston JA, Burns GC, Klotman PE. The human immunodeficiency virus (HIV) epidemic and HIV-associated nephropathy. Semin Nephrol 1998;18(4):373-7
  32. Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002;62(6):2301-10. doi: 10.1046/j.1523-1755.2002.00674.x
  33. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004;15(8):2169-77. doi: 10.1097/01.ASN.0000135051.62500.97
  34. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995;25(4):534- 42. doi: 10.1016/0272-6386(95)90120-5
  35. Thomas DB, Franceschini N, Hogan SL et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006;69(5):920-6. doi: 10.1038/sj.ki.5000160
  36. Sethi S, Zand L, Nasr SH et al. Focal and segmental glomerulosclerosis: clinical and kidney biopsy correlations. Clin Kidney J 2014; 7(6):531-7. doi: 10.1093/ckj/sfu100
  37. Kambham N, Markowitz GS, Valeri AM et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 2001;59(4):1498-509. doi: 10.1046/j.1523- 1755.2001.0590041498.x
  38. Praga M, Morales E, Herrero JC et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 1999;33(1):52-8. doi: 10.1016/s0272-6386(99)70257-x
  39. Chagnac A, Weinstein T, Herman M et al. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 2003;14(6):1480-6. doi: 10.1097/01.asn.0000068462.38661.89
  40. Lepori N, Zand L, Sethi S et al. Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. Clin Kidney J 2018;11(2):179-190. doi: 10.1093/ckj/sfx143
  41. Caridi G, Bertelli R, Carrea A et al. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol 2001;12(12):2742-6
  42. Ashraf S, Kudo H, Rao J et al. Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment. Nat Commun 2018;17;9(1):1960. doi: 10.1038/s41467- 018-04193-w
  43. Нефрология. Клинические рекомендации. По ред. Шилов ЕМ, Смирнов АВ, Козловская НЛ. ГОЭТАР-Медиа, 2016
  44. Guruswamy Sangameswaran KD, Baradhi KM. Focal Segmental Glomerulosclerosis. 2020 Aug 24. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan
  45. Yuan YD, Gong XW, Yang YH. Meta-analysis of risk factors for recurrent pulmonary thromboembolism. Zhonghua Yi Xue Za Zhi 2012;92(34):2419-25
  46. Leslom AN, Alrawiah ZMS, Al-Asmari AMA at al. Prevalence of pulmonary thromboembolism in nephrotic syndrome patients: A systematic review and meta- analysis. J Family Med Prim Care 2020;9(2):497-501. doi: 10.4103/jfmpc.jfmpc_1076_19
  47. Li SJ, Tu YM, Zhou CS, Zhang LH, Liu ZH. Risk factors of venous thromboembolism in focal segmental glomerulosclerosis with nephrotic syndrome. Clin Exp Nephrol 2016;20(2):212-7. doi: 10.1007/s10157-015-1149-4
  48. Cattran DC, Appel GB, Hebert LA et al. A randomized trial of cyclosporine in patients with steroidresistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999;56(6):2220-6. doi: 10.1046/j.1523- 1755.1999.00778.x
  49. Ramachandran R, Kumar V, Rathi M et al. Tacrolimus therapy in adult-onset steroid- resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. Nephrol Dial Transplant 2014;29(10):1918-24. doi: 10.1093/ndt/gfu097
  50. Meyrier A, Noel LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Societe de Nephrologie. Kidney Int 1994;45(5):1446-56. doi: 10.1038/ki.1994.189
  51. Meyrier A, Condamin MC, Broneer D. Treatment of adult idiopathic nephrotic syndrome with cyclosporin A: minimal-change disease and focal-segmental glomerulosclerosis. Collaborative Group of the French Society of Nephrology. Clin Nephrol 1991;35 Suppl 1:S37-42
  52. Ghiggeri GM, Catarsi P, Scolari F et al. Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study. Clin Ther 2004;26(9):1411-8. doi: 10.1016/j.clinthera.2004.09.012
  53. Segarra A, Vila J, Pou L et al. Combined therapy of tacrolimus and corticosteroids in cyclosporinresistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002;17(4):655- 62. doi: 10.1093/ndt/17.4.655
  54. Ramachandran R, Kumar V, Rathi M et al. Tacrolimus therapy in adult-onset steroid- resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. Nephrol Dial Transplant 2014;29(10):1918-24. doi: 10.1093/ndt/gfu097
  55. Gulati F, Sinha F, Gupta F et al. Treatment with tacrolimus and prednisolone ispreferable to intravenous cyclophosphamide as the initial therapy for children with steroid- resistantnephrotic syndrome. Кidney International 2012;82:1130-1135. doi:10.1038/ki.2012.238
  56. Gyamlani G, Molnar MZ, Lu JL et al. Association of serum albumin level and venous thromboembolic events in a large cohort of patients with nephrotic syndrome. Nephrology Dialysis Transplantation 2017;32(1):157-164. doi: 10.1093/ndt/gfw227
  57. Laurin LP, Nachman PH, Foster BJ. Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis of the Literature. Can J Kidney Health Dis 2017;4:2054358117692559. doi: 10.1177/2054358117692559
  58. Chiou Y-Y, Lee Y-C, Chen M-J. Cyclosporine-based immunosuppressive therapy for patients with steroid-resistant focal segmental glomerulosclerosis: a meta-analysis. Curr Med Res Opin 2017;33(8):1389-1399. doi: 10.1080/03007995.2017.1322567
  59. Sprangers B, Meijers B, Appel G. FSGS: Diagnosis and Diagnostic Work-Up. Biomed Res Int 2016;4632768. doi: 10.1155/2016/4632768
  60. Thomas DB. Focal segmental glomerulosclerosis: a morphologic diagnosis in evolution. Arch Pathol Lab Med 2009;133(2):217-23
  61. Fuiano G, Comi N, Magri P et al. Serial morphometric analysis of sclerotic lesions in primary "focal" segmental glomerulosclerosis. J Am Soc Nephrol 1996;7(1):49-55
  62. Schwartz MM, Korbet SM. Primary focal segmental glomerulosclerosis: pathology, histological variants, and pathogenesis. Am J Kidney Dis 1993;22(6):874-83
  63. Sadowski CE, Lovric S, Ashraf S et al. A single-gene cause in 29.5% of cases of steroid- resistant nephrotic syndrome. J Am Soc Nephrol 2015;26(6):1279-89. doi: 10.1681/ASN.2014050489
  64. Lu L, Wan H, Yin Y et al. The p.R229Q variant of the NPHS2 (podocin) gene in focal segmental glomerulosclerosis and steroid-resistant nephrotic syndrome: a meta-analysis. Int Urol Nephrol 2014;46(7):1383-93. doi: 10.1007/s11255-014-0676-3
  65. Korbet SM. Treatment of primary FSGS in adults. J Am Soc Nephrol 2012;23(11):1769- 76. doi: 10.1681/ASN.2012040389
  66. Xie X, Liu Y, Perkovic V et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis 2016;67(5):728-741
  67. Geng DF, Sun WF, Yang L et al. Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials. J Renin Angiotensin Aldosterone Syst 2014;15(1):44-51. doi: 10.1177/1470320312474054
  68. Medjeral-Thomas N, Ziaj S, Condon M et al. Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome. Clin J Am Soc Nephrol 2014; 9(3):478-83. doi: 10.2215/CJN.07190713
  69. Ha JT, Neuen BL, Cheng LP et al. Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med 2019;171(3):181-189. doi: 10.7326/M19-0087
  70. Chen HY, Ou SH, Huang CW et al. Efficacy and Safety of Direct Oral Anticoagulants vs Warfarin in Patients with Chronic Kidney Disease and Dialysis Patients: A Systematic Review and Meta-Analysis. Clin Drug Investig 2021;41(4):341-351. doi: 10.1007/s40261-021-01016-7
  71. Troyanov S, Wall CA, Miller JA et al. Focal and Segmental Glomerulosclerosis: Definition and Relevance of a Partial Remission. J Am Soc Nephrol 2005;16(4):1061-8. doi: 10.1681/ASN.2004070593
  72. Goumenos DS, Tsagalis G, El Nahas AM et al. Immunosuppressive treatment of idiopathic focal segmental glomerulosclerosis: a five-year follow-up study. Nephron Clin Pract 2006;104(2):c75-82. doi: 10.1159/000093993
  73. Pei Y, Cattran D, Delmore T et al. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am J Med 1987;82(5):938-44. doi: 10.1016/0002-9343(87)90155-0
  74. Schwartz MM, Evans J, Bain R, Korbet SM. Focal segmental glomerulosclerosis: prognostic implications of the cellular lesion. J Am Soc Nephrol 1999;10(9):1900-7
  75. Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994;23(6):773-83. doi: 10.1016/s0272-6386(12)80128-4
  76. Ponticelli C, Villa M, Banfi G et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999;34(4):618-625
  77. Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998;32(1):72-9
  78. Banfi G, Moriggi M, Sabadini E et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991;36(2):53-9
  79. Pokhariyal S, Gulati S, Prasad N et al. Duration of optimal therapy for idiopathic focal segmental glomerulosclerosis. J Nephrol 2003;16(5):691-6
  80. Braun N, Schmutzler F, Lange C et al. Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. Cochrane Database Syst Rev 2008;2008(3):CD003233. doi: 10.1002/14651858.CD003233.pub2
  81. Chávez-Mendoza CA, Niño-Cruz JA, Correa-Rotter R et al. Calcineurin Inhibitors With Reduced-Dose Steroids as First-Line Therapy for Focal Segmental Glomerulosclerosis. Kidney Int Rep 2018;4(1):40-47. doi: 10.1016/j.ekir.2018.08.010
  82. Duncan N, Dhaygude A, Owen J et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004;19(12):3062-7. doi: 10.1093/ndt/gfh536
  83. Jiang X, Shen W, Xu X et al. Immunosuppressive therapy for steroid-resistant nephrotic syndrome: a Bayesian network meta-analysis of randomized controlled studies. Clin Exp Nephrol 2018;22(3):562-569. doi: 10.1007/s10157-017-1484-8
  84. Li HY, Zhang X, Zhou T et al. Efficacy and safety of cyclosporine a for patients with steroid-resistant nephrotic syndrome: a meta-analysis. BMC Nephrol 2019;20(1):384. doi: 10.1186/s12882-019-1575-8
  85. Ponticelli C, Rizzoni G, Edefonti A et al. A randomized trial of cyclosporine in steroid- resistant idiopathic nephrotic syndrome. Kidney Int 1993;43:1377-1384
  86. Bhaumik SK, Majumdar A, Barman SC. Comparison of pulse methylprednisolone vs cyclosporin based therapy in steroid resistant focal segmental glomerulosclerosis [abstract]. Indian Journal of Nephrology 2002;12
  87. Heering P, Braun N, Mullejans R et al. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004;43(1):10-8. doi: 10.1053/j.ajkd.2003.09.027
  88. El-Husseini A, El-Basuony F, Mahmoud I et al. Long-term effects of cyclosporine in children with idiopathic nephrotic syndrome: a single-centre experience. Nephrol Dial Transplant 2005;20:2433-2438
  89. Ponticelli C, Edefonti A, Ghio L et al. Cyclosporin versus cyclophosphamide for patients with steroiddependent and frequently relapsing idiopathic nephrotic syndrome: a multicentre randomized controlled trial. Nephrol Dial Transplant 1993;8:1326-1332
  90. Gipson DS, Trachtman H, Kaskel FJ et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011;80(8):868-78. doi: 10.1038/ki.2011.195
  91. Nayagam LS, Ganguli A, Rathi M et al. Mycophenolate mofetil or standard therapy for membranous nephropathy and focal segmental glomerulosclerosis: a pilot study. Nephrology Dialysis Transplantation 2008;23(6):1926-1930. doi: 10.1093/ndt/gfm538
  92. Choi MJ, Eustace JA, Gimenez LF et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61(3):1098-114. doi: 10.1046/j.1523- 1755.2002.00214.x
  93. Cattran DC, Wang MM, Appel G et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004;62(6):405-11. doi: 10.5414/cnp62405
  94. Geary DF, Farine M, Thorner P, Baumal R. Response to cyclophosphamide in steroid- resistant focal segmental glomerulosclerosis: a reappraisal. Clinical Nephrology 1984;22(3):109-113
  95. Martinelli R, Pereira LJ, Silva OMM et al. Cyclophosphamide in the treatment of focal segmental glomerulosclerosis. Braz J Med Biol Res 2004;37(9):1365-72.doi: 10.1590/s0100-879x2004000900011
  96. Ren H, Shen P, Li X et al. Tacrolimus versus cyclophosphamide in steroid-dependent or steroid-resistant focal segmental glomerulosclerosis: a randomized controlled trial. Am J Nephrol. 2013;37(1):84-90
  97. Hansrivijit P, Cheungpasitporn W, Thongprayoon C, Ghahramani N. Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis. BMC Nephrol 2020;21(1):134. doi: 10.1186/s12882-020-01797-7
  98. Fernandez-Fresnedo G, Segarra A, González E et al. Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2009;4(8):1317-23. doi: 10.2215/CJN.00570109
  99. Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines – application to the individual patient. Kidney Int 2012;82(8):840-856
  100. Sandoval D, Poveda R, Draibe J et al. Efficacy of mycophenolate treatment in adults with steroid-dependent/frequently relapsing idiopathic nephrotic syndrome. Clin Kidney J 2017;10(5):632-638
  101. Cheng X et al. Efficacy and safety of rituximab in adult frequent-relapsing or steroid-dependent minimal change disease or focal segmental glomerulosclerosis: a systematic review and meta-analysis. Clinical Kidney Journal 2021;14(4):1042-1054
  102. Chitalia VC, Wells JE, Robson RA et al. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 1999;56(6):2236-42
  103. Wehrmann M, Bohle A, Held H et al. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990;33(3):115-122
  104. Laurin LP, Gasim AM, Derebail VK et al. Renal Survival in Patients with Collapsing Compared with Not Otherwise Specified FSGS. Clin J Am Soc Nephrol 2016;11(10):1752-1759

  1. Deegens JK, Assmann KJ, Steenbergen EJ et al. Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? Neth J Med 2005;63(10):393-8
  2. Beaman M, Howie AJ, Hardwicke J et al. The glomerular tip lesion: a steroid responsive nephrotic syndrome. Clin Nephrol 1987;27(5):217-21

Для продолжения работы требуется Registration
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Table of contents

Данный блок поддерживает скрол*